Drugs
Scientists at the Human Genome Project are discovering genetic markers for various diseases, including cancer, at an unprecedented rate. The identification of these disease genes is paving the way for the development of DNA-based diagnostic and prognostic assessments. This momentum is expected to revolutionize the pharmaceutical industry, enabling the creation
Drugs
Targeted Genetics Corporation, a leader in the development of gene and cell therapy products, has reported its first quarter 1998 results, marking a significant milestone in the company's journey towards advancing innovative treatments for life-threatening diseases. Although the company incurred a net loss of $3.8 million, attributed
Drugs
CuraGen Corporation, a biotechnology company pioneering the application of assembly-line genomics, announced its financial results for the first quarter of 1998. The company reported a revenue increase of 61% over the same period in 1997, reaching $1,989,572. The net loss before preferred dividends was $3,167,513, or
Drugs
British Biotech, one of the country's leading independent drug developers, is under intense scrutiny following allegations that trial results of one of its major products were suspicious. The company's chief executive, Keith McCullagh, has sold shares after being informed of problems with one of the company&
Drugs
Medical Industries of America Inc. has announced its acquisition of 100% of Pharmacy Care Specialists Inc., a privately held, closed-door pharmacy company specializing in delivering prescription pharmaceuticals to the Adult Congregal Living Facilities (ACLF) industry in Florida. The acquisition provides a strategic opportunity for Medical Industries to expand its services
Drugs
McKesson Corporation has signed a two-year agreement with Hennepin County Medical Center, a county-owned facility providing primary, acute, and tertiary care, as well as trauma services. The agreement designates McKesson as the primary supplier for pharmaceutical purchases, with anticipated revenues exceeding $26 million over the term of the agreement. In
Pharmaceutical industry
ProCyte Corporation, a healthcare company developing and marketing products for tissue repair, skin health, and hair care, reported a net loss of $1,049,081 in the quarter ended March 31, 1998. This loss represents a significant reduction from the first quarter of 1997, when the company reported a net
Pharmaceutical industry
Snyder Communications, Inc. has made a significant move in the pharmaceutical market by acquiring CLI Pharma S.A., a leading provider of outsourced pharmaceutical sales and marketing solutions in France. The acquisition, valued at $25 million, complements Snyder's recent purchase of Publimed Promotions and establishes the company as
Pharmaceutical industry
Monsanto's innovative approach to drug research and development has yielded a significant breakthrough in the treatment of arthritis, thanks to the tireless efforts of Chief Scientist Philip Needleman. Despite conventional wisdom and the skepticism of Wall Street analysts, Monsanto invested deeply in its G.D. Searle & Co.
Pharmaceutical industry
Omnicare, a leading geriatric pharmaceutical care company, has acquired Medical Communications Software, Inc. (MCS) in a pooling-of-interests transaction. This acquisition expands Omnicare's line of long-term care software systems and increases its software installations to over 4,700 facilities, making it the largest provider of resident assessment and care
Pharmaceutical industry
In a stunning reversal, pharmaceutical company G.D. Searle & Co. is poised for a major comeback, thanks to its new arthritis medication, Celebra. Despite years of criticism from analysts and investors, Celebra's promising test results have the medical community and Wall Street singing a new tune. With
Pharmaceutical industry
Immunex, a leading biopharmaceutical company, and ArQule, a chemistry company specializing in accelerated drug discovery, announced a collaboration to discover and develop new products for the treatment of inflammatory disorders. This partnership will utilize ArQule's Mapping Array program to identify small molecule therapeutics based on a new chemokine
